{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:05:03Z","timestamp":1777881903334,"version":"3.51.4"},"reference-count":86,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med\ufffdInsights\ufffdPathol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>The discovery of the SARS-CoV-2 Omicron (B.1.1.529) variant has sparked alarm globally because of its rapid rate of infection and trespassing acquired immunity due to vaccination or natural infection. This heavily mutated variant is rapidly spreading around the world. Infected individuals with the Omicron variant may suffer from flu-like symptoms, and infected with the Delta variant frequently report low oxygen levels, high pulse rates, and a loss of smell and taste. Also, the Omicron variant causes asymptomatic or mild disease so far, and not any severe illness as like Delta, and this new variant has a 15% to 80% reduced risk of hospitalization than the Delta variant. Scientists are worried about the possibility of escaping the immunity by the Omicron variants and subvariants among fully vaccinated and recovered COVID-19 patients. Two doses of available vaccines are found to be partially ineffective in protecting this new variant, therefore, the third dose as a booster is recommended to enhance antibody level. Moreover, some antiviral drugs significantly reduce hospitalization or death among mild to severe COVID-19 patients. All authorized antiviral drugs are effective against viral replication for most SARS-CoV-2 variants, and particularly some monoclonal antibodies may not now be effective in treating COVID-19 patients. There is an urgent need to update existing vaccines, develop more effective and newer vaccines as well as additional monoclonal antibodies to counter Omicron. Therefore, along with close monitoring of Omicron characteristics, the present study suggests that health safety guidelines, mass immunization, early diagnosis, and search for effective antiviral drugs should be the approaches to fight against newer SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1177\/2632010x221124908","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T08:53:13Z","timestamp":1663663993000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health"],"prefix":"10.1177","volume":"15","author":[{"given":"Md.","family":"Rabiul Islam","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waheeda","family":"Nasreen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramisa","family":"Anjum","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shahriar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[{"name":"Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohiuddin","family":"Ahmed Bhuiyan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"bibr1-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27546"},{"key":"bibr2-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27503"},{"key":"bibr3-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X221076068"},{"key":"bibr4-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/23337214221117419"},{"key":"bibr5-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1515\/openhe-2022-0002"},{"key":"bibr6-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.807474"},{"key":"bibr7-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2022.100320"},{"key":"bibr8-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.3245"},{"key":"bibr9-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-022-00352-6"},{"key":"bibr10-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27633"},{"key":"bibr11-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1515\/openhe-2022-0010"},{"key":"bibr12-2632010X221124908","first-page":"1823","volume":"76","author":"Hossain MJ","year":"2021","journal-title":"Arch Razi Inst"},{"key":"bibr13-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27635"},{"key":"bibr14-2632010X221124908","unstructured":"World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021. Accessed December 26, 2021. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern"},{"key":"bibr15-2632010X221124908","first-page":"109","volume":"33","author":"Rahman FI","year":"2021","journal-title":"J Basic ClinPhysiolPharmacol"},{"key":"bibr16-2632010X221124908","unstructured":"European Centre for Disease Prevention and Control. Weekly epidemiological update: Omicron variant of concern (VOC) \u2013 week 50. December 19, 2021. Accessed December 26, 2021. https:\/\/www.ecdc.europa.eu\/en\/news-events\/weekly-epidemiological-update-omicron-variant-concern-voc-week-50-data-19-december-2021"},{"key":"bibr17-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.545"},{"key":"bibr18-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27574"},{"key":"bibr19-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.671"},{"key":"bibr20-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27516"},{"key":"bibr21-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02844-0"},{"key":"bibr22-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X221075584"},{"key":"bibr23-2632010X221124908","volume":"375","author":"Mahase E.","year":"2021","journal-title":"BMJ"},{"key":"bibr24-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3062"},{"key":"bibr25-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3013"},{"key":"bibr26-2632010X221124908","unstructured":"Centers for Disease Control and Prevention. CDC stands up new disease forecasting center. 2021. Accessed January 4, 2022. https:\/\/www.cdc.gov\/media\/releases\/2021\/p0818-disease-forecasting-center.html"},{"key":"bibr27-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o66"},{"key":"bibr28-2632010X221124908","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) dashboard. Accessed June 25, 2022. https:\/\/covid19.who.int\/"},{"key":"bibr29-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04411-y"},{"key":"bibr30-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/prot.26250"},{"key":"bibr31-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2023329"},{"key":"bibr32-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.357"},{"key":"bibr33-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3144"},{"key":"bibr34-2632010X221124908","first-page":"8012","volume":"25","author":"Meo SA","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"bibr35-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v2i1.71"},{"key":"bibr36-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03807-6"},{"key":"bibr37-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2023330"},{"key":"bibr38-2632010X221124908","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. Accessed June 25, 2022. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/"},{"key":"bibr39-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2206576"},{"key":"bibr40-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27526"},{"key":"bibr41-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3103"},{"key":"bibr42-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101146"},{"key":"bibr43-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112816"},{"key":"bibr44-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081172"},{"key":"bibr45-2632010X221124908","unstructured":"CNBC. Three new studies suggest omicron has lower hospitalization risk and is milder than other variants. 2021. Accessed January 4, 2022. https:\/\/www.cnbc.com\/2021\/12\/23\/omicron-variant-has-lower-risk-of-hospitalization-studies-suggest.html"},{"key":"bibr46-2632010X221124908","unstructured":"University of Edinburg THE. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. 2021. Accessed January 4, 2022. https:\/\/www.research.ed.ac.uk\/en\/publications\/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-"},{"key":"bibr47-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00462-7"},{"key":"bibr48-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X221099889"},{"key":"bibr49-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27207"},{"key":"bibr50-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2021.100153"},{"key":"bibr51-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.3539"},{"key":"bibr52-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27919"},{"key":"bibr53-2632010X221124908","doi-asserted-by":"crossref","unstructured":"Wolter N, Jassat W, Walaza S. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant. MedRxiv, 2021. Accessed January 4, 2022. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.21.21268116v1","DOI":"10.1016\/S0140-6736(22)00017-4"},{"key":"bibr54-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.15.426911"},{"key":"bibr55-2632010X221124908","unstructured":"World Health Organization. Update on Omicron. 2021. Accessed January 4, 2022. https:\/\/www.who.int\/news\/item\/28-11-2021-update-on-omicron."},{"key":"bibr56-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03794-8"},{"key":"bibr57-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04465-y"},{"key":"bibr58-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.029"},{"key":"bibr59-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102234"},{"key":"bibr60-2632010X221124908","first-page":"21267417","volume":"2021","author":"Cele S","year":"2021","journal-title":"medRxiv"},{"key":"bibr61-2632010X221124908","unstructured":"ALJAZEERA. COVID: Study suggests AstraZeneca booster works against Omicron. 2021. Accessed January 4, 2022. https:\/\/www.aljazeera.com\/news\/2021\/12\/23\/astrazeneca-says-booster-jab-works-against-omicron-study-finds"},{"key":"bibr62-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345"},{"key":"bibr63-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.17.473248"},{"key":"bibr64-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211058562"},{"key":"bibr65-2632010X221124908","unstructured":"Centers for Disease Control and Prevention. New SARS-CoV-2 variant of concern identified: Omicron (B.1.1.529) variant. 2021.Accessed January 4, 2022. https:\/\/emergency.cdc.gov\/han\/2021\/han00459.asp"},{"key":"bibr66-2632010X221124908","unstructured":"Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases (NCIRD). Accessed January 4, 2022. https:\/\/www.cdc.gov\/ncird\/index.html"},{"key":"bibr67-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106716"},{"key":"bibr68-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"bibr69-2632010X221124908","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. FDA News Release, 2021. Accessed December 26, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"},{"key":"bibr70-2632010X221124908","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. FDA News Release, 2021. Accessed December 26, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"bibr71-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab361"},{"key":"bibr72-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"bibr73-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103595"},{"key":"bibr74-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4017904"},{"key":"bibr75-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247"},{"key":"bibr76-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2117814"},{"key":"bibr77-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179124"},{"key":"bibr78-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2713"},{"key":"bibr79-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27540"},{"key":"bibr80-2632010X221124908","unstructured":"Centers for Disease Control and Prevention. Potential Rapid Increase of Omicron Variant Infections in the United States. 2019. Accessed January 4, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/forecasting\/mathematical-modeling-outbreak.html"},{"key":"bibr81-2632010X221124908","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations. 2022. Accessed January 14, 2022. https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL"},{"key":"bibr82-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211073014"},{"key":"bibr83-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211065628"},{"key":"bibr84-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121449"},{"key":"bibr85-2632010X221124908","doi-asserted-by":"crossref","first-page":"e069317","DOI":"10.1136\/bmj-2021-069317","volume":"377","author":"Suthar AB","year":"2022","journal-title":"BMJ"},{"key":"bibr86-2632010X221124908","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab079"}],"container-title":["Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2632010X221124908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2632010X221124908","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2632010X221124908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:56:41Z","timestamp":1777597001000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2632010X221124908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":86,"alternative-id":["10.1177\/2632010X221124908"],"URL":"https:\/\/doi.org\/10.1177\/2632010x221124908","relation":{},"ISSN":["2632-010X","2632-010X"],"issn-type":[{"value":"2632-010X","type":"print"},{"value":"2632-010X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"2632010X221124908"}}